趋化因子CXC家族基因多态性与丙型肝炎抗病毒治疗效果的相关性分析

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (700 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the association of chemokine family CXC gene polymorphism with response to therapy in chronic hepatitis C virus patients, so as to timely intervene and improve the curative effect in the course of treatment. Methods: A total of 282 patients with chronic hepatitis C were enrolled in this study. The patients were treated for 48 weeks and were followed up for 24 weeks with the treatment of polyethylene glycol interferon α combined with ribavirin.The results of sustained virological response(SVR) were observed. All patients were genotyped by TaqManMGB fluorescence probe PCR. Logistic regression analysis was used to analyze the influencing factors of SVR. Results: After 48 weeks of followup,180(63.83%) HCV patients achieved SVR. Multivariate Logistic regression analysis showed that the high level of thyrotropin(OR=1.22,95% CI=1.04-1.42) and the low level of blood glucose(OR=0.85,95%CI=0.72-0.99) were conducive to increasing the SVR rate. The high level of baseline HCVRNA(OR=0.72,95% CI=0.56-0.99) was not conducive to increasing SVR. However, CXCL9 rs10336(OR=0.97,95%CI=0.40-2.33),rs3733236 (OR=0.89,95%CI=0.43-1.87)and CXCL12 rs1801157(OR=1.31,95%CI=0.80-1.86)were not significantly associated with SVR. Conclusion: Baseline HCVRNA, serum thyrotropin and blood glucose were the independent influencing factors of SVR in patients with chronic hepatitis C.There was no significant association of antiviral therapy with chemokine gene polymorphism in hepatitis C patients.

Received: 12 September 2017

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2018/V28/I02/144

［1］Lingala S,Ghany MG.Natural history of hepatitis C\[J\].Gastroenterol Clin North Am,2015,44(4): 717-734.
［2］Bertino G, Ardiri A, Proiti M, et al. Chronic hepatitis C: This and the new era of treatment\[J\]. World J Hepatol,2016,8(2):92-106.
［3］Taherkhani R,Farshadpour F.Epidemiology of hepatitis C virus in Iran\[J\].World J Gastroenterol, 2015,21(38):10790-10810.
［4］张艳茹. 维生素D对慢性丙型肝炎抗病毒治疗疗效和预后的影响分析\[D\]. 广州:南方医科大学,2014.
［5］Saldanha J, Gerlich W, Lelie N, et al.An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques\[J\]. Vox Sanguinis, 2001, 80(1):63-71.
［6］陈海英. 慢性丙型肝炎患者干扰素治疗前后丙肝病毒基因部分序列分析\[D\]. 长春:吉林大学,2007.
［7］梅儒齐. 单核苷酸多态性与丙肝患者临床表现及抗病毒治疗应答的相关性研究\[D\]. 长春:吉林大学,2016.
［8］Rong X, Lu L, Wang J, et al. Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains\[J\]. PLoS One,2012,7(12):e52467.
［9］Kitson MT, Dore GJ, George J, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection\[J\]. J Hepatol,2013,58(3):467-472.
［10］孙艳. 两种维生素在慢性肝病患者中浓度和疗效及分子机理的理论研究\[D\]. 济南:山东理工大学,2013.
［11］房熙峰. 检测慢性丙肝患者血清中自身抗体的临床价值\[J\]. 世界最新医学信息文摘,2017,17(11):106-107.
［12］张彦芳,张彦敏,孙春秀,等. 丙型肝炎持续病毒学免疫应答影响因素分析\[J\]. 标记免疫分析与临床,2016,23(02):186-189.
［13］王瑞,刘玉佩,钱静,等. 慢性丙型肝炎抗病毒治疗后患者体内持续病毒学应答率影响因素分析\[J\]. 山东医药,2013,53(27):7-10.
［14］Poordad F,Bronowicki JP,Gordon SC,et al.Factors that predict response of patients with hepatitis C virus infection to boceprevir\[J\].Gastroenterology,2012,143(3):608-618.
［15］Petit JM,Bour JB,GallandJos C,et al.Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C \[J\].J Hepatol,2001,35(2):279-283.
［16］Manos MM,Darbinian J,Rubin J,et al.The effect of hepatitis C treatment response on medical costs:a longitudinal analysis in an integrated care setting\[J\]. J Manag Care Pharm,2013,19(6): 438-447.
［17］Limou S,Coulonges C,Herbeck JT,et al. Multiplecohort genetic association study reveals cxcr6 as a new chemokine receptor involved in longterm nonprogression to aids\[J\].J Infect Dis,2010, 202(6):908-915.
［18］Estrabaud E,Vidaud M,Marcellin P,et al.Genomics and HCV infection: Progression of fibrosis and treatment response\[J\]. J Hepatol,2012,57(5):1110-1125.
［19］Butera D,Marukian S,Iwamaye AE,et al.Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis c\[J\]. Blood,2005, 106(4):1175-1182.
［20］PinedaTenor D,Berenguer J,Jim nezSousa MA,et al.Cxcl9, cxcl10 and cxcl11 polymorphisms are associated with sustained virologic response in hiv/hcvcoinfected patients\[J\].J Clin Virol,2014, 61(3):423-429.